top of page
  • Jonathan Poyer

The Doctor Is In - Biotech in July

A conversation regarding the Therapeutics market and why it is standing out from other segments of biotech and health sciences.

Other topics covered:

  • Urogen (URGN) and its triple-digit performance

  • What is going on with SMID stocks

  • An assessment of obesity drugs and its potential impact on markets and society

8 views0 comments


bottom of page